| Page 170 | Aplastic Anemia and MDS International Foundation

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogenei

Author(s): 
Kröger N, Bacher U, Bader P, Böttcher S, Borowitz MJ, Dreger P, Khouri I, Macapinlac HA, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS
Primary Author: 
Kröger N
Journal Title: 
Biol Blood Marrow Transplant
Original Publication Date: 
Jun 2010

Relapse has become the major cause of treatment failure after allogeneic stem cell transplantation. Outcome of patients with clinical relapse after transplantation generally remains poor, but intervention prior to florid relapse improves outcome for certain hematologic malignancies. To detect early relapse or minimal residual disease, sensitive methods such as molecular genetics, tumor-specific molecular primers,

Bone Marrow Diseases: 
myelodysplastic syndromes (MDS)

Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.

Author(s): 
Götze K, Platzbecker U, Giagounidis A, Haase D, Lübbert M, Aul C, Ganser A, Germing U, Hofmann WK
Primary Author: 
Götze K
Journal Title: 
Ann Hematol
Original Publication Date: 
Jun 2010

Bone Marrow Diseases: 
myelodysplastic syndromes (MDS)

Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Author(s): 
Fey MF, Dreyling M; ESMO Guidelines Working Group
Primary Author: 
Fey MF
Journal Title: 
Ann Oncol
Original Publication Date: 
May 2010

No abstract available.

Bone Marrow Diseases: 
myelodysplastic syndromes (MDS)

5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.

Author(s): 
Buckstein R, Yee K, Wells RA; Canadian Consortium on Evidence-based Care in MDS.
Primary Author: 
Buckstein R
Journal Title: 
Cancer Treat Rev
Original Publication Date: 
Jun 2010

BACKGROUND:

Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoiesis that results in peripheral blood cytopenias

Bone Marrow Diseases: 
myelodysplastic syndromes (MDS)